Fewer than 2 in 100 eligible women currently use menopausal hormone therapy, despite decades of accumulated evidence that, for many women, the benefits outweigh the risks. A major 2026 study traces exactly how usage collapsed, and a separate, confirmed regulatory change this year may finally start shifting that number back up.
The Numbers Behind the Decline
A Mayo Clinic Proceedings study, published June 1, 2026, analyzed a large nationwide U.S. health database of women 40 and older from 2007 to 2023 and found menopausal hormone therapy use fell from 4.4% to just 1.7% over that period. Even more striking, usage among women aged 50 to 59 — the group most likely to see meaningful benefit from starting therapy — had dropped to only 3.5% by 2023. Researchers attribute the collapse largely to lingering fear from the Women’s Health Initiative study of the early 2000s, which was widely (and, in hindsight, often inaccurately) reported in ways that overstated hormone therapy’s risks for the broader population of women considering it.
What the FDA Actually Changed This Year
In 2026, the FDA removed the black-box warning — its most serious safety label — from multiple menopausal hormone therapy products, a change confirmed across several independent sources including Harvard Health and the Society of Gynecologic Oncology. This isn’t a minor label adjustment; a black-box warning is reserved for the most serious potential risks, and its removal reflects a broader reassessment within the medical and regulatory community of how those original risk estimates apply to the women actually considering treatment today, particularly those starting therapy within several years of menopause onset.
The Research Behind the Shift
Part of what’s driving this reassessment is data like a Danish study finding that women who started estradiol around age 50 saw a roughly 50% reduction in all-cause mortality, with no corresponding increase in breast cancer risk in that population. Clinical guidance has also moved away from the older “lowest dose, shortest time, under five years” framing toward a more individualized approach to duration, recognizing that blanket time limits weren’t well supported by the more recent evidence for many women.
None of this means hormone therapy is risk-free or right for everyone — individual health history, family history, and specific risk factors still matter, and this is exactly the kind of decision that benefits from a real conversation with a doctor rather than a blanket recommendation either way. What’s changed is the framing: from a treatment presumed risky until proven otherwise, to one weighed on an individual basis against genuinely reassessed data.
What Hormone Therapy Actually Involves
Menopausal hormone therapy isn’t a single standardized product; it comes in several forms depending on individual health history. Women who still have a uterus generally need combined estrogen-and-progestogen therapy, since estrogen alone can increase the risk of uterine lining changes without progestogen to balance it, while women who’ve had a hysterectomy can typically use estrogen alone. Delivery methods also vary meaningfully — oral tablets, transdermal patches, gels, and vaginal preparations are all options, and the delivery method itself can affect certain risk factors, including clotting risk, which is part of why a personalized conversation with a doctor matters more than a single generic recommendation.
Why This Gap Matters
A persistent barrier beyond the regulatory history is clinician training. Many physicians received little formal menopause-specific education during medical school or residency, which has left a real gap in how confidently hormone therapy gets discussed as an option at all, independent of what the current evidence actually supports. That gap, combined with two decades of lingering public fear from outdated reporting, helps explain why usage stayed near historic lows even as newer, more nuanced data accumulated. Some medical organizations have specifically pointed to this training gap as a target for improvement, alongside the regulatory change, as a way to close the distance between what current evidence supports and what patients are actually being offered in routine care.
What This Means If You’re Considering It
If you’ve previously been told hormone therapy wasn’t an option for you, or never had it raised as one, the regulatory and evidence shifts described here are a reasonable basis for revisiting that conversation, particularly if you’re within several years of menopause onset and dealing with symptoms like hot flashes, sleep disruption, or vaginal dryness that are meaningfully affecting daily life. Bringing this specific research to a doctor directly, rather than assuming the earlier advice still reflects current guidance, is a reasonable way to make sure you’re being offered a decision based on where the evidence actually stands now.
Frequently Asked Questions
Does the black-box warning removal mean hormone therapy has no risks?
No. It reflects a reassessment of how the original warning applied broadly, not a declaration that the therapy is risk-free. Individual risk factors still need to be discussed with a doctor.
Is it too late to start hormone therapy years after menopause began?
The benefit-risk profile does appear to shift with how soon after menopause onset someone starts therapy, which is part of why this is a conversation to have with a doctor rather than something to self-determine from general information.
Why did so many women stop hearing about this as an option?
Largely due to the lingering effect of early-2000s reporting on the Women’s Health Initiative study, combined with limited menopause-specific training among many clinicians, both of which the research described above points to directly.
Does hormone therapy help with anything besides hot flashes?
Yes — it’s also commonly used for vaginal dryness, sleep disruption tied to night sweats, and bone density protection, though the specific benefits relevant to you depend on your individual symptoms and health history, which is again a conversation for your doctor rather than a generic list.
Final Thoughts
The gap between how few women currently use hormone therapy and what current evidence actually supports for many of them is substantial, and it’s rooted in outdated fear more than current data. If you’re navigating menopause symptoms, this is a genuinely worthwhile conversation to bring to a doctor directly, rather than ruling it out based on decades-old headlines.
More wellness guides grounded in current research are available in the Wellness section at gemifys.com.
